Reviva Pharmaceuticals Holdings has the GF Score of 26, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Reviva Pharmaceuticals Holdings
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Reviva Pharmaceuticals Holdings GF Score Related Terms
RVPH vs AIM, BOLT, BRTX: GF Score Comparison
For the Biotechnology subindustry, Reviva Pharmaceuticals Holdings's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Reviva Pharmaceuticals Holdings GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Reviva Pharmaceuticals Holdings's GF Score distribution charts can be found below:
* The bar in red indicates where Reviva Pharmaceuticals Holdings's GF Score falls into.
Reviva Pharmaceuticals Holdings (RVPH) has a GF Score of 26 as of Jul. 04, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Reviva Pharmaceuticals Holdings and its competitors. This is near median its historical median of 24.00. Over the past decade, Reviva Pharmaceuticals Holdings' GF Score has ranged from 14.00 to 42.00.
Is Reviva Pharmaceuticals Holdings' GF Score too high?
Reviva Pharmaceuticals Holdings' current GF Score of 26 is near median its 10-year median of 24.00. Over the past 10 years, this metric has ranged from a low of 14.00 to a high of 42.00. Overall, Reviva Pharmaceuticals Holdings has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Reviva Pharmaceuticals Holdings' GF Score compare to AIM and BOLT?
Reviva Pharmaceuticals Holdings' GF Score of 26 can be compared against companies in the Biotechnology industry. Historically, Reviva Pharmaceuticals Holdings' own GF Score has ranged from 14.00 to 42.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Reviva Pharmaceuticals Holdings and its competitors. Reviva Pharmaceuticals Holdings's current GF Score is 26, which is near median its own 10-year median of 24.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Reviva Pharmaceuticals Holdings stock overvalued right now?
Reviva Pharmaceuticals Holdings (RVPH) has a current GF Score of 26. The current GF Score is 26, which is near median its 10-year median of 24.00. Reviva Pharmaceuticals Holdings' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Reviva Pharmaceuticals Holdings (RVPH), the current GF Score is 26 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Reviva Pharmaceuticals Holdings Business Description
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063), which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis, and its other drug candidate is RP1208.
26GF Score
Get the complete analysis for RVPH
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RVPH has been successfully added to your 